EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Survival motor neuron protein is the optimal biomarker for evaluating the risdiplam treatment

Tamaki Kato, Noriko Otsuki, Mamoru Yokomura, Naoko Shima, Kota Kajima, Moeka Shioya, Hayato Suzuki, Hidetaka Wakabayshi, Kayoko Saito

Brain and Development · 2025

DOI: 10.1016/j.braindev.2025.104410 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain and Development, 2025. Verfasst von Tamaki Kato und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Genetics, Tokyo Women's Medical University, Tokyo, Japan. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal, Survival of Motor Neuron 1 Protein. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Atrophy, SpinalSurvival of Motor Neuron 1 ProteinHumansMaleBiomarkersFemaleChildChild, PreschoolAdolescentJapanAzo CompoundsPyrimidines

Stichwörter der Autor:innen

BiomarkersMuscular atrophy, spinalRisdiplamSurviving motor neuron protein

Substanzen

BiomarkersRisdiplamSurvival of Motor Neuron 1 ProteinAzo CompoundsPyrimidines

Autor:innen und Institutionen

  • Institute of Medical Genetics, Tokyo Women's Medical University, Tokyo, Japan.
  • Department of Rehabilitation Medicine, Tokyo Women's Medical University, Tokyo, Japan.
  • Department of Rehabilitation Medicine, Toho University Graduate School of Medicine, Tokyo, Japan.
  • Institute of Medical Genetics, Tokyo Women's Medical University, Tokyo, Japan. Electronic address: saito.kayoko@twmu.ac.jp.

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development

Zitieren

APA

Kato, T., Otsuki, N., Yokomura, M., Shima, N., Kajima, K., Shioya, M., Suzuki, H., Wakabayshi, H., & Saito, K. (2025). Survival motor neuron protein is the optimal biomarker for evaluating the risdiplam treatment. Brain and Development. https://doi.org/10.1016/j.braindev.2025.104410

Vancouver

Kato T, Otsuki N, Yokomura M, Shima N, Kajima K, Shioya M, et al. Survival motor neuron protein is the optimal biomarker for evaluating the risdiplam treatment. Brain and Development. 2025. doi:10.1016/j.braindev.2025.104410

BibTeX
@article{Kato2025,
  author = {Kato, Tamaki and Otsuki, Noriko and Yokomura, Mamoru and Shima, Naoko and Kajima, Kota and Shioya, Moeka and Suzuki, Hayato and Wakabayshi, Hidetaka and Saito, Kayoko},
  title = {Survival motor neuron protein is the optimal biomarker for evaluating the risdiplam treatment},
  journal = {Brain and Development},
  year = {2025},
  doi = {10.1016/j.braindev.2025.104410}
}
Kostenlos starten →